TherapeuticsMD (NASDAQ:TXMD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Other equities research analysts also recently issued reports about the company. Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a research report on Wednesday, December 20th. Oppenheimer set a $10.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Deutsche Bank set a $9.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Cantor Fitzgerald reissued a “buy” rating and set a $31.00 target price on shares of TherapeuticsMD in a research report on Wednesday, November 29th. Finally, Jefferies Group reissued a “buy” rating and set a $15.00 target price on shares of TherapeuticsMD in a research report on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $14.50.
Shares of TherapeuticsMD (NASDAQ:TXMD) opened at $6.15 on Friday. The stock has a market capitalization of $1,330.00, a PE ratio of -15.77 and a beta of 1.06. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The business had revenue of $4.42 million for the quarter, compared to the consensus estimate of $5.36 million. During the same period last year, the business earned ($0.13) earnings per share. The firm’s revenue for the quarter was down 19.7% compared to the same quarter last year. equities research analysts predict that TherapeuticsMD will post -0.37 EPS for the current fiscal year.
In other TherapeuticsMD news, Director Tommy G. Thompson purchased 5,000 shares of the business’s stock in a transaction on Friday, December 8th. The stock was purchased at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the purchase, the director now directly owns 3,555 shares in the company, valued at $22,076.55. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 23.92% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its stake in TherapeuticsMD by 13.0% during the third quarter. Bank of New York Mellon Corp now owns 25,877,864 shares of the company’s stock worth $136,894,000 after purchasing an additional 2,985,846 shares during the period. JPMorgan Chase & Co. lifted its stake in TherapeuticsMD by 40.4% during the third quarter. JPMorgan Chase & Co. now owns 22,027,855 shares of the company’s stock worth $112,783,000 after purchasing an additional 6,340,346 shares during the period. Vanguard Group Inc. lifted its stake in TherapeuticsMD by 4.4% during the second quarter. Vanguard Group Inc. now owns 10,231,081 shares of the company’s stock worth $53,918,000 after purchasing an additional 429,211 shares during the period. State Street Corp lifted its stake in TherapeuticsMD by 14.9% during the second quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after purchasing an additional 583,094 shares during the period. Finally, Voya Investment Management LLC lifted its stake in TherapeuticsMD by 33.4% during the second quarter. Voya Investment Management LLC now owns 2,959,107 shares of the company’s stock worth $15,595,000 after purchasing an additional 741,588 shares during the period. Hedge funds and other institutional investors own 73.69% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Zacks Investment Research Downgrades TherapeuticsMD (TXMD) to Sell” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/14/zacks-investment-research-downgrades-therapeuticsmd-txmd-to-sell.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.